BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221205
DTEND;VALUE=DATE:20221209
DTSTAMP:20260516T042854
CREATED:20220819T112000Z
LAST-MODIFIED:20220819T112000Z
UID:34927-1670198400-1670543999@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy for Neurological Disorders
DESCRIPTION:Delivering the Next Wave of Gene Therapies to the CNS \nWith systemic toxicity challenges plaguing the AAV field\, direct administration for CNS indications creates an ideal target for gene therapy. This is an exciting year for the neurological space with clinical data to show and new biotechs coming out of the woodwork to release the next wave of gene therapies with more advanced CNS targeting for a wider selection of neurological targets. \nThe 4th Annual Gene Therapy for Neurological Disorders Summit will unite gene therapy developers with an industry-focused agenda across 4 days and 2 dedicated tracks of content to solve the preclinical\, translational and clinical challenges of targeting a wide range of neurodevelopmental and neurodegenerative disorders with both ‘first’ and ‘next’ generation gene therapies. \nJoin the expanding audience of gene therapy experts to: \n\nStreamline CNS drug delivery devices for improved brain biodistribution\nDiscover novel vectors for CNS specificity & tropism\nOptimize gene therapy strategy for pediatric & adult neurological disorders\n\nTo know more visit: https://ter.li/rluqrj
URL:https://www.pharmajournalist.com/event/4th-annual-gene-therapy-for-neurological-disorders/
LOCATION:The Westin Seaport District\, 425 Summer St\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221205
DTEND;VALUE=DATE:20221208
DTSTAMP:20260516T042854
CREATED:20220919T115535Z
LAST-MODIFIED:20220919T115535Z
UID:35224-1670198400-1670457599@www.pharmajournalist.com
SUMMARY:4th Annual Cell Therapy Analytical Development Summit
DESCRIPTION:Cell Therapy Analytical Development Summit US is back for its fourth year\, taking place in Boston (December 5-7). Join 180+ colleagues from analytical development\, process development\, quality control and regulatory affairs\, to standardize analytical testing and take advantage of unrivalled content across: \n\n3-days\n6 deep-dive workshops\n2 tracks\n\nSeize an unmatched opportunity to delve into cell potency\, safety\, viability\, sterility and more across both autologous and allogeneic cell therapy products. \nPlease use this URL – https://ter.li/ghwxjk
URL:https://www.pharmajournalist.com/event/4th-annual-cell-therapy-analytical-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221206
DTEND;VALUE=DATE:20221209
DTSTAMP:20260516T042854
CREATED:20220914T121744Z
LAST-MODIFIED:20220914T121744Z
UID:35170-1670284800-1670543999@www.pharmajournalist.com
SUMMARY:5th Commercializing Clinically Validated Digital Therapeutics Summit
DESCRIPTION:The 5th Commercializing Clinically Validated Digital Therapeutics Summit\, designed with DTx companies\, pharma and clinicians\, will return this December to address the industry’s major challenges such as improving user experience\, clinical trial development\, and standing out in a crowded market through open discussion and case-study led presentations.   \nWhether you’re a veteran at commercializing clinically validated digital therapeutics\, looking for partnerships\, or a new entrant to the field\, you’ll leave this conference with practical lessons and essential connections needed to supercharge DTx commercial ambitions across 2022 and beyond. \nTo know more visit: https://ter.li/5e6hqd
URL:https://www.pharmajournalist.com/event/5th-commercializing-clinically-validated-digital-therapeutics-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221206
DTEND;VALUE=DATE:20221209
DTSTAMP:20260516T042854
CREATED:20221024T225543Z
LAST-MODIFIED:20221025T102843Z
UID:35606-1670284800-1670543999@www.pharmajournalist.com
SUMMARY:4th Annual Targeted Radiopharmaceuticals Summit Europe
DESCRIPTION:The long-awaited 4th Annual Targeted Radiopharmaceuticals Summit Europe is returning in-person in Amsterdam on December 6-8\, 2022! \nAs the only devoted meeting for large pharma\, biotech and pioneering academics\, this meeting unites key stakeholders under the mutual and ambitious objective of advancing radioligand candidates to commercialisation through rigorous clinical rationale and reliable supply chain design. \nDownload the full Event Guide to learn what the 29+ expert speakers will present on\, including: \n\n\n\nMeeting the newest contenders to enter the field including Ariceum Therapeutics and TRIMT\nDiscovering new targeting systems that are opening avenues to treating more cancers with Tagworks and Ratio Therapeutics\nGetting the most up-to-date information on current radionuclide stocks and how the world’s leading isotope producers are increasing their production and variety of products with Duke University\nEnhancing your trial design to conduct the most rigorous trials with help from leading clinical stage companies with Oncoinvent\nThe ability to showcase your work and meet new people across dedicated sessions and have the meetings that will help you build vital collaborations\n\n\n\nAccess the official Event Guide here to see the complete agenda and speaker line up.
URL:https://www.pharmajournalist.com/event/4th-annual-targeted-radiopharmaceuticals-summit-europe/
LOCATION:Leonardo Royal Amsterdam\, Paul van Vlissingenstraat 24\, Amsterdam\, 1096 BK\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221206
DTEND;VALUE=DATE:20221208
DTSTAMP:20260516T042854
CREATED:20221110T115946Z
LAST-MODIFIED:20221110T115946Z
UID:35768-1670284800-1670457599@www.pharmajournalist.com
SUMMARY:2nd Next-Generation Food Allergy Drug Development Summit
DESCRIPTION:The field of food allergy therapeutics is continuing to boom as companies flood the news with fresh IND clearances and clinical readouts. The race to market for the next food allergy therapy is well and truly on\, but access to funding and large patient cohorts\, along with the need for novel IgE biomarkers and better diagnostics (to name a few challenges) are holding drug developers back from even faster progress. \nThe 2nd Next-Generation Food Allergy Drug Development Summit is reuniting this December as the only industry-focused meeting dedicated to unveiling the complexities of food allergies with novel oral immunotherapies\, antibody-based therapeutics and microbiome-based approaches to accelerate ground-breaking treatments for the ever-increasing unmet medical need. \nJoin us in-person for the first time in Boston as the food allergy community comes together to unravel the complex regulatory landscape\, identify and validate novel clinical biomarkers to aid patient selection and explore novel routes of administration to innovate long-lasting\, next-generation treatments. \nTo know more visit: https://bit.ly/3GlzzRp
URL:https://www.pharmajournalist.com/event/2nd-next-generation-food-allergy-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR